• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Inovio Pharmaceuticals Inc.

    12/5/25 2:03:43 PM ET
    $INO
    Medical/Dental Instruments
    Health Care
    Get the next $INO alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    INOVIO PHARMACEUTICALS INC

    (Name of Issuer)


    COMMON STOCK

    (Title of Class of Securities)


    45773H409

    (CUSIP Number)


    11/28/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    45773H409


    1Names of Reporting Persons

    FMR LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    9,846,664.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    9,846,664.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    9,846,664.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    14.8 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    45773H409


    1Names of Reporting Persons

    Abigail P. Johnson
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    9,846,664.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    9,846,664.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    14.8 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    INOVIO PHARMACEUTICALS INC
    (b)Address of issuer's principal executive offices:

    660 W. GERMANTOWN PIKE,SUITE 110,PLYMOUTH MEETING,PA,US,19462
    Item 2. 
    (a)Name of person filing:

    FMR LLC
    (b)Address or principal business office or, if none, residence:

    245 Summer Street, Boston, Massachusetts 02210
    (c)Citizenship:

    Not applicable
    (d)Title of class of securities:

    COMMON STOCK
    (e)CUSIP No.:

    45773H409
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    9846664.00
    (b)Percent of class:

    14.8  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Please see the responses to Items 5 and 6 on the cover page.

     (ii) Shared power to vote or to direct the vote:

    0.00

     (iii) Sole power to dispose or to direct the disposition of:

    9846664.00

     (iv) Shared power to dispose or to direct the disposition of:

    0.00

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of INOVIO PHARMACEUTICALS INC. The interest of Fidelity Small Cap Growth Fund, in the COMMON STOCK of INOVIO PHARMACEUTICALS INC, amounted to 5980194.00 shares or 9.0% of the total outstanding COMMON STOCK at 11/28/2025.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    See attached Exhibit 99.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    FMR LLC
     
    Signature:Stephanie J. Brown
    Name/Title:Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
    Date:12/04/2025
     
    Abigail P. Johnson
     
    Signature:Stephanie J. Brown
    Name/Title:Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson**
    Date:12/04/2025

    Comments accompanying signature:  * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.
    Exhibit Information

    Please see Exhibit 99 for 13d-1(k) (1) agreement.

    Get the next $INO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INO

    DatePrice TargetRatingAnalyst
    7/9/2025$5.00Overweight
    Piper Sandler
    5/14/2024$20.00Overweight
    Stephens
    1/25/2024$4.00Perform → Outperform
    Oppenheimer
    11/9/2022Buy → Hold
    Maxim Group
    11/1/2022$2.00Neutral → Underperform
    BofA Securities
    7/19/2022$5.00 → $4.00Sector Perform
    RBC Capital Mkts
    5/11/2022Outperform → Perform
    Oppenheimer
    3/2/2022$6.00 → $5.00Sector Perform
    RBC Capital
    More analyst ratings

    $INO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    INOVIO to Participate in December Investor Conferences

    PLYMOUTH MEETING, Pa., Nov. 18, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that it will participate in the following investor conferences: Piper Sandler 37th Annual Healthcare Conference (New York, NY)Date: Tuesday, December 2Time: 8:30-8:55 AM ETFormat: Fireside Chat Webcast: https://bit.ly/44af19l (live webcast and replay available for 90 days after the event) Oppenheimer Movers in Rare D

    11/18/25 8:05:00 AM ET
    $INO
    Medical/Dental Instruments
    Health Care

    INOVIO Announces Pricing of $25 Million Public Offering

    PLYMOUTH MEETING, Pa., Nov. 11, 2025 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten public offering of 13,158,000 shares of its common stock at a public offering price of $1.90 per share. All of the shares of common stock in the offering are being sold by INOVIO. The offering is expected to close on or about November 12, 2025, subject to the satisfaction of customary closing conditions. INOVIO also granted the underwriters an option for a period of 30 days to purc

    11/11/25 8:40:00 AM ET
    $INO
    Medical/Dental Instruments
    Health Care

    INOVIO Announces Proposed Public Offering

    PLYMOUTH MEETING, Pa., Nov. 10, 2025 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares of common stock in the proposed offering will be sold by INOVIO. INOVIO intends to grant the underwriter a 30-day option to purchase additional shares of its common stock in an amount up to 15% of the shares of common stock offered in the public offering under the same terms and conditions. The prop

    11/10/25 6:09:00 PM ET
    $INO
    Medical/Dental Instruments
    Health Care

    $INO
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Inovio Pharmaceuticals Inc.

    SCHEDULE 13G - INOVIO PHARMACEUTICALS, INC. (0001055726) (Subject)

    12/5/25 2:03:43 PM ET
    $INO
    Medical/Dental Instruments
    Health Care

    SEC Form 8-K filed by Inovio Pharmaceuticals Inc.

    8-K - INOVIO PHARMACEUTICALS, INC. (0001055726) (Filer)

    11/12/25 6:16:08 AM ET
    $INO
    Medical/Dental Instruments
    Health Care

    SEC Form 424B5 filed by Inovio Pharmaceuticals Inc.

    424B5 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Filer)

    11/12/25 6:13:02 AM ET
    $INO
    Medical/Dental Instruments
    Health Care

    $INO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Sumner Michael John converted options into 2,916 shares, increasing direct ownership by 20% to 17,850 units (SEC Form 4)

    4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)

    7/1/25 4:08:06 PM ET
    $INO
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Executive Officer Shea Jacqueline Elizabeth

    4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)

    5/21/25 4:58:59 PM ET
    $INO
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Scientific Officer Humeau Laurent

    4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)

    5/21/25 4:58:48 PM ET
    $INO
    Medical/Dental Instruments
    Health Care

    $INO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on Inovio Pharma with a new price target

    Piper Sandler initiated coverage of Inovio Pharma with a rating of Overweight and set a new price target of $5.00

    7/9/25 8:30:13 AM ET
    $INO
    Medical/Dental Instruments
    Health Care

    Stephens initiated coverage on Inovio Pharma with a new price target

    Stephens initiated coverage of Inovio Pharma with a rating of Overweight and set a new price target of $20.00

    5/14/24 8:01:14 AM ET
    $INO
    Medical/Dental Instruments
    Health Care

    Inovio Pharma upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded Inovio Pharma from Perform to Outperform and set a new price target of $4.00

    1/25/24 7:27:17 AM ET
    $INO
    Medical/Dental Instruments
    Health Care

    $INO
    Leadership Updates

    Live Leadership Updates

    View All

    Avacta Appoints David Liebowitz, M.D., Ph.D. as Chief Medical Officer and Yulii Bogatyrenko as Advisor in Business Development

    LONDON and PHILADELPHIA, July 01, 2025 (GLOBE NEWSWIRE) -- Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, today announces the appointment of David Liebowitz, M.D., Ph.D. as Chief Medical Officer (CMO) and Yulii Bogatyrenko as an advisor in business development. Dr. Liebowitz will lead the Company's clinical strategy and execution as it continues to advance its pipeline of targeted cancer therapies and Mr. Bogatyrenko will add additional strength to the Group's business development strategy. Dr. Liebowitz is a seasoned hematologist-oncologist and drug development leader with more than 30 years of experience across academia and indust

    7/1/25 7:00:00 AM ET
    $INO
    Medical/Dental Instruments
    Health Care

    INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accomplishments

    PLYMOUTH MEETING, Pa., Jan. 9, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today highlighted anticipated milestones for 2025 and key accomplishments from 2024 in advance of upcoming investor meetings. "Based on the progress achieved in 2024, we anticipate 2025 to be a transformational year for INOVIO as we move closer to our goal of becoming a commercial-stage company providing a breakthrough therapy for pati

    1/9/25 8:04:00 AM ET
    $INO
    Medical/Dental Instruments
    Health Care

    INOVIO Announces Appointment of Steven Egge as Chief Commercial Officer

    Mr. Egge brings over 25 years of biopharmaceutical experience building commercial organizations and successfully launching novel therapeutic products INOVIO poised to become a commercial-stage company with plans to submit a Biologics License Application for INO-3107 in second half of 2024 under U.S. Food and Drug Administration's Accelerated Approval Pathway PLYMOUTH MEETING, Pa., July 2, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the appointment of Steven Egge as Chief Commercial Officer. Mr. Egge will le

    7/2/24 4:05:00 PM ET
    $INO
    Medical/Dental Instruments
    Health Care

    $INO
    Financials

    Live finance-specific insights

    View All

    INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights

    Completed rolling Biologics License Application (BLA) submission seeking accelerated approval for lead candidate INO-3107; requested priority review Expect to receive file acceptance by year end 2025 with potential PDUFA date in mid-2026 if request for priority review grantedCommercial preparations continuing for potential launch in mid-2026 if INO-3107 is approved by FDA Results from Phase 1 proof-of-concept trial evaluating INOVIO's next generation DNA-Encoded Monoclonal Antibody (DMAb™) technology published in Nature MedicinePLYMOUTH MEETING, Pa., Nov. 10, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help trea

    11/10/25 4:05:00 PM ET
    $INO
    Medical/Dental Instruments
    Health Care

    INOVIO to Report Third Quarter 2025 Financial Results on November 10, 2025

    PLYMOUTH MEETING, Pa., Oct. 27, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious diseases, today announced that its third quarter 2025 financial results will be released after the market close on November 10, 2025. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss the financial results and provide a general business update. The live webcast will be available online at

    10/27/25 8:05:00 AM ET
    $INO
    Medical/Dental Instruments
    Health Care

    INOVIO to Report Second Quarter 2025 Financial Results on August 12, 2025

    PLYMOUTH MEETING, Pa., Aug. 4, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious diseases, today announced that its second quarter 2025 financial results will be released after the market close on August 12, 2025. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss the financial results and provide a general business update. The live webcast will be available online at ht

    8/4/25 4:05:00 PM ET
    $INO
    Medical/Dental Instruments
    Health Care

    $INO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Inovio Pharmaceuticals Inc.

    SC 13G - INOVIO PHARMACEUTICALS, INC. (0001055726) (Subject)

    4/26/24 4:01:17 PM ET
    $INO
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Inovio Pharmaceuticals Inc. (Amendment)

    SC 13G/A - INOVIO PHARMACEUTICALS, INC. (0001055726) (Subject)

    1/22/24 10:20:28 AM ET
    $INO
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Inovio Pharmaceuticals Inc. (Amendment)

    SC 13G/A - INOVIO PHARMACEUTICALS, INC. (0001055726) (Subject)

    7/10/23 2:07:33 PM ET
    $INO
    Medical/Dental Instruments
    Health Care